Skip to Content

Label Changes for:

Jalyn (dutasteride and tamsulosin) capsules

June 2011

Changes have been made to the WARNINGS and PRECAUTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – June 2011 



Increased Risk of High-grade Prostate Cancer
  • revisions to the labeling regarding the risk of high-grade prostate cancer and the effect of Jalyn on serum prostate specific antigen (PSA) levels. It also provides updated information regarding male breast cancer and includes 4 year results from the CombAT study (ARI40005).